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Abstract 
Background: Head and neck cancer (HNC) is one of the most common cancers worldwide and its incidence is 
reported to be increasing in resource-limited countries. There is a paucity of published data regarding head and neck 
cancers in Tanzania, and Bugando Medical Centre in particular. This study describes the clinicopathological profile of 
HNC in our local setting and highlights the challenges in the management of this disease.
Methods: This was a retrospective study of histopathologically confirmed cases of head and neck cancers treated at 
Bugando Medical Center between January 2009 and December 2013.
Results: A total of 346 patients (M:F = 2.1:1) were studied representing 9.5 % of all malignancies. The median age of 
patients was 42 years. Cigarette smoking (76.6 %) and heavy alcohol consumption (69.9 %) were the most frequently 
identified risk factors for head and neck cancer. The majority of patients (95.9 %) presented late with advanced stages. 
Twenty-five (7.2 %) patients were HIV positive with a median CD4+ count of 244 cells/μl. The oral cavity (37.3 %) 
was the most frequent anatomical site affected. The most common histopathological type was carcinomas (59.6 %) 
of which 75.7 % were squamous cell carcinoma. A total of 196 (56.6 %) patients underwent surgical procedures for 
HNC. Radiotherapy and chemotherapy was reported in 9.5 and 16.8 % of patients, respectively. Only 2 (0.6 %) patients 
received chemo-radiation therapy. The mortality rate was 24.4 %. The overall 5-year survival rate (5-YSR) was 20.6 %. 
The predictors of overall 5-YSR were age of patient at diagnosis, stage of disease, extent of lymph node involvement, 
HIV seropositivity and CD4+ count <200 cells/μl (P < 0.001). Local recurrence was reported in 22 (23.4 %) patients 
and this was significantly associated with positive resection margins, stage of the tumor and presence of metastasis at 
diagnosis and non-adherence to adjuvant therapy (P < 0.001).
Conclusion: Head and neck cancers are not uncommon at Bugando Medical Centre and show a trend towards a 
relative young age at diagnosis and the majority of patients present late with advanced stage cancer. Therefore, public 
enlightenment, early diagnosis, and effective cost-effective treatment and follow-up are urgently needed to improve 
outcomes of these patients in our environment.
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Background
Head and neck cancers are malignant neoplasms occur-
ring in the nasal cavities, paranasal sinuses, nasophar-
ynx, hypopharynx, oropharynx, ear, scalp, oral cavity and 
salivary glands [1]. They constitute a major public health 
concern throughout the world and are an important 
cause of morbidity and mortality [1–3]. Head and neck 
cancers are associated with high morbidity because there 
is interference with vital functions of life such as breath-
ing, swallowing, speech, hearing, vision, taste and smell-
ing [2].
Epidemiologically, head and neck cancers have been 
reported to be the tenth most common cancer world-
wide [3] and there has been a significant increase in the 
Open Access
BMC Research Notes
*Correspondence:  drphillipoleo@yahoo.com 
1 Department of Surgery, Catholic University of Health and Allied 
Sciences-Bugando, Mwanza, Tanzania
Full list of author information is available at the end of the article
Page 2 of 9Gilyoma et al. BMC Res Notes  (2015) 8:772 
global incidence of head and neck cancer over the past 
decade [4, 5]. At present, more than 650,000 new cases 
of head and neck cancer are diagnosed each year world-
wide [5], and their incidence appears to be increasing in 
developing countries [4]. Globally, head and neck cancers 
constitute 5–50  % of all cancers [6], and 5–8  % of total 
body cancers in Europe and America [7–9], whilst in 
India it forms about 30 % of all cancers [10, 11]. Overall, 
head and neck cancers seem to affect black Africans at a 
younger age than in Caucasians [11]. Men are affected far 
more often than women [10, 11].
Etiological factors determining individual susceptibil-
ity to head and neck cancers are still not fully known [2, 
12–14]. The pattern of occurrence of head and neck can-
cers varies between races and from one geographical area 
to another [2, 13]. Excess tobacco and alcohol consump-
tion are the most important of the known predisposing 
factors [7]. The association of these predisposing factors 
with head and neck cancers makes these cancers prevent-
able and controllable following early diagnosis [13, 14].
Diverse histological types of tumors are found in the 
head and neck region. More than 90 % of head and neck 
cancers are of epithelial origin, of which squamous cell 
carcinoma constitutes the greatest majority [15, 16]. 
Other histological types include lymphomas, blastomas, 
sarcomas and neuroendocrine tumors [16].
The management of head and neck cancer is com-
plex and requires a multidisciplinary approach involv-
ing medical oncologists, radiation oncologists, head and 
neck surgeons, radiologists, speech therapists, social 
workers, psychologists, plastic and/or reconstructive 
surgeons, dentists with particular interest and expertise 
in head and neck cancer [17]. However, the management 
of cancers of the head and neck cancers remains a major 
challenge to medical practitioners because of the varied 
nature of histological patterns (sites of origin, natural his-
tory, and varied treatment modalities involving extensive, 
delicate, and sometimes repeated surgeries, radiotherapy 
and chemotherapy) [2, 7, 16, 17]. Thus the disease places 
great strain on health resources [2]. This strain is even 
more apparent in developing countries, such as Tanzania, 
where the bulk of health bills are borne by individuals 
and families since health insurance is not available.
The treatment of head and neck cancers varies accord-
ing to the primary site, tumor stage, patient treatment 
preference, and practitioner’s expertise. Neck lymph 
nodes approach depends on the primary site and extent 
of disease [18]. The clinical stage of the disease at diag-
nosis often determines the prognosis and survival rate of 
a patient with head and neck cancers, with the best out-
comes seen in patients diagnosed at an early stage [15, 
16]. However, the outcome of treatment of head and neck 
cancers in limited-resource countries such as Tanzania 
has been poor because the majority of these patients pre-
sent late to the hospital with an advanced stage of the dis-
ease and only palliative care is possible [19]. This is partly 
due to a lack of community awareness on the importance 
of early reporting to hospital for the early diagnosis and 
treatment of this condition, poor accessibility to health-
care facilities, limited diagnostic and therapeutic facili-
ties, poor accessibility to adjuvant therapy and the high 
cost of care.
There is a paucity of information regarding head and 
neck cancer in Tanzania and Bugando Medical Centre in 
particular. This is partly due to a lack of published local 
data regarding this condition and the lack of cancer reg-
istries in this region. This study was designed to describe 
the clinicopathological pattern of head and neck cancer 
and highlight the challenging problem in the manage-
ment of this disease in our local setting.
Methods
This was a retrospective study of histopathologically con-
firmed cases of head and neck cancer treated at Bugando 
Medical Center between January 2009 and December 
2013. Bugando Medical Centre is a consultant, tertiary 
care and teaching hospital for the Catholic University of 
Health and allied Sciences-Bugando (CUHAS-Bugando) 
and has a bed capacity of 1000. It serves as a referral 
center for tertiary specialist care for a catchment popu-
lation of approximately 13 million people. The hospital 
has a newly established oncology department which pro-
vides care for all patients with histopathologically-proven 
cancers, including head and neck cancers. However, the 
department does not provide radiotherapy services at 
the moment due to lack of this facility at our center. As a 
result, patients requiring this modality of treatment have 
to travel long distances to receive radiotherapy at the 
Tanzania Oncology Centre located a considerable dis-
tance from the study area.
The study included all patients who presented to 
Bugando Medical Centre with histologically-confirmed 
cases of head and neck cancers during the period studied. 
Patients with incomplete data were excluded from the 
study.
The details of patients were retrieved from patients’ 
files kept in the medical record department, the surgi-
cal wards, operating theater and histopathology labora-
tory. Information retrieved included socio-demographic 
data, clinical presentation, anatomical site, tumor stage, 
histopathological type and grade, presence of metastasis 
(nodal, distant), HIV status, treatment modalities, and 
outcome and follow-up. HIV testing was performed using 
the Tanzania HIV Rapid Test Algorithm and CD4+ count 
using FACS or FACSCALIBUR (BD Biosciences, USA). 
A determination of CD4+ count was only performed 
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in HIV-positive patients. Using CD4 cell counts severe 
immune suppression was defined by patients with CD4 
200 cells per μl whilst moderate immune suppression 
is formed by patients with CD4 >200 cells per μl. Head 
and neck cancer was diagnosed based on a histopatho-
logical examination. The clinical stage of the disease 
was assigned to each patient by using TNM (AJCC can-
cer staging manual); this is a staging system which is an 
expression of the anatomical extent of the disease based 
on the extent of the primary tumor (T), absence or pres-
ence of and extent of regional lymph node metastasis (N) 
and absence or presence of distant metastasis. Depend-
ing on the site, biopsy specimens were obtained by exci-
sional, incisional, curettage or punch biopsies. Tissue 
specimens were submitted for histopathological exami-
nation. Frozen section study was not available during the 
period of the study.
Treatment modalities included surgery, chemotherapy 
and radiotherapy. Patients were followed up for up to 
5  years or death. Survival analysis was carried out with 
survival defined as the time between the date of com-
mencement of treatment and the date of last follow-up or 
death. The recurrence of disease was confirmed by physi-
cal findings, radiological studies, endoscopic examination 
with biopsy and surgery.
Statistical analysis
Data collected were analyzed using SPSS computer soft-
ware version 17.0 (SPSS, Inc., Chicago, IL, USA). Data 
were summarized in the form of proportions and fre-
quency tables for categorical variables. The median (and 
IQR) and ranges were calculated for continuous vari-
ables, whereas proportions and frequency tables were 
used to summarize categorical variables. The Chi square 
(χ2) test was used to test for the significance of associa-
tion between the independent (predictor) and dependent 
(outcome) variables in the categorical variables. The level 
of significance was considered as P  <  0.05. Multivariate 
logistic regression analysis was used to determine predic-
tor variables that predicted the outcome.
Ethical consideration
Ethical approval to conduct the study was obtained from 
the CUHAS-Bugando/Bugando Medical Centre joint 
institutional ethic review committee before the com-
mencement of the study.
Results
Out of 4011 patients who were registered with malig-
nancies at Bugando Medical Center during the 5-year 
period, 382 were cases of head and neck cancers repre-
senting 9.5  % of all malignancies. Out of these, 346 of 
them constituting 90.6  % had documentary evidence of 
a confirmed histological diagnosis. Hence, subsequent 
data analysis was based on the 346 histologically con-
firmed cases. The age of patients at diagnosis ranged 
from 3 to 82 years with a median age of 42 years (inter-
quartile range 40–46  years). The modal age group at 
presentation was 41–50  years accounting for 28.9  % of 
cases. Two hundred and forty-one (69.7 %) patients were 
aged 40  years and above. Out of the 346 patients, 234 
(67.6 %) were males and 112 (32.4 %) were females with 
a male to female ratio of 2.1:1. The majority of patients, 
289 (83.5  %) were mainly farmers from the rural areas 
located a considerable distance from Mwanza City. Most 
patients, 214 (61.8  %), had either primary or no formal 
education and more than three-quarters of them were 
unemployed. More than 90  % of the study patients had 
no identifiable health insurance.
The duration between disease onset and presentation 
for all the patients ranged from 3 to 24 months with 104 
(30.1  %) patients presenting within 6  months of onset 
of illness and 242 (69.9 %) patients after 6 months. Two 
hundred-fourteen (61.8  %) patients visited the herbalist 
in the course of their illness before presenting to the hos-
pital. Smoking and alcohol consumption were reported 
by 265 (76.6  %) and 242 (69.9  %) patients, respectively. 
Smoking and alcohol consumption habit were more com-
mon in male patients than in females and this differences 
were statistically significant (P < 0.001).
The oral cavity was the most frequent anatomical site 
for the head and neck cancers accounting for 37.3  % of 
patients (Table 1). TNM staging was documented in only 
148 (42.8 %) patients. Of this, only 6 (4.1 %) patients were 
identified as being in early stages (TNM stage I–II) and 
142 (95.9 %) patients were presented in advanced stages 
(stage III–IV). Lymph node involvement at the time of 
diagnosis was recorded in 102 (29.5 %) patients of which 
34 (33.3 %) presented with N1 nodal disease, 20 (19.6 %) 
with N2a nodal disease and 48 (47.1 %) with N2b nodal 
disease. Distant metastasis was recorded in 98 (28.3  %) 
patients. The most common histopathological type was 
carcinomas which afflicted 206 (59.6  %) patients. Out 
of the 206 carcinomas, 156 (75.7 %) were squamous cell 
carcinoma. Lymphomas ranked second in 88 (25.4  %) 
patients followed by sarcomas in 38 (11.0  %) and neu-
roendocrine tumors in 14 (4.0 %) patients.
Plain radiographs of the skull, neck and chest per-
formed in 234 (67.6 %) patients revealed abnormalities 
in 112 (47.9  %) patients. Abdominal ultrasound done 
in 26 (7.5  %) revealed liver metastasis in 12 (46.2  %) 
patients. Computed tomography (CT scan) and mag-
netic resonance imaging (MRI) were not available, 
which challenged our management, as this limited the 
tumour staging. Complete blood count, hemoglobin 
levels and ESR were done in all patients. More than 
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three quarter of the patients had hemoglobin lev-
els less than 10.0 gm/dl and ESR in the first hour was 
found ranging between 12 and 80 mm/1 h. Serological 
investigations for HIV infection revealed that 25 (7.2 %) 
patients were HIV positive. Of these, 6 (24.0 %) patients 
were known cases on highly active anti-retroviral ther-
apy (HAART) and the remaining 19 (76.0  %) patients 
were newly diagnosed patients. There was no statisti-
cally significant difference between HAART treatment 
and head and neck cancers (HNC) prevalence and out-
come (p > 0.001). CD4+ count distribution among HIV 
positive patients ranged from 145 to 866 cells/μl with 
the median CD4+ count of 244 cells/μl. A total of eight 
(32.0 %) HIV patients had CD4+ count below 200 cells/
μl and the remaining 17 (68.0  %) patients had CD4+ 
count of >200 cells/μl. The proportion of HIV infected 
patients was significantly higher in patients with lym-
phomas (12.5 %) and sarcomas (26.2 %) than in patients 
with carcinomas (1.9  %) and neuroendocrine tumors 
(0 %) (P < 0.001) (Table 2).
A total of 196 (56.6 %) patients underwent surgical pro-
cedure of which tumor excision was the most common 
surgical procedure performed in 61.2 % of cases (Table 3). 
Radiotherapy was indicated in 130 (37.6 %) patients. Of 
these, only 33 (9.5  %) patients received this modality of 
treatment. Chemotherapy was prescribed in 76 (22.0 %) 
patients. However, only 58 (16.8 %) completed the treat-
ment. Only 2 (0.6  %) patients received chemo-radiation 
therapy.
In this study, 84 patients died in-hospital giving a mor-
tality rate of 24.3  %. The commonest causes of deaths 
were advanced malignancy, complications of HIV/AIDS 
and sepsis. According to multivariate logistic regres-
sion analysis, advanced age (>65 years), late presentation 
(>6 months), HIV seropositivity, CD4+ count below 200 
cells/μl, stage of disease, and presence of metastasis at 
the time of diagnosis were found to be the main predic-
tors of mortality (P < 0.001).
Follow-up of patients among survivors (262) ranged 
from 3 to 62 months with a median of 24 months (inter-
quartile range 20–26 months). At the end of the follow-
up period, only 94 (35.9 %) patients of the survivors were 
available for follow-up and the remaining 168 (64.1  %) 
patients were lost to follow-up. Out of 94 patients who 
were available for follow-up, only 54 patients were alive 
and well at the end of 5  years, giving an overall 5-year 
survival rate of 20.6  %. The 5-year survival rate for 
patients with early disease was higher than for those 
with advanced disease (P  =  0.016). The predictors of 
overall 5-year survival rate were age of patient at diag-
nosis (P = 0.012), stage of disease (P = 0.041), extent of 
lymph node involvement (P = 0.011), HIV seropositivity 
(P = 0.004), CD4+ count below 200 cells/μl (P = 0.001). 
Evidence of cancer recurrence was reported in 22 
(23.4 %) patients. Positive resection margins, stage of the 
tumor and presence of metastasis at the time of diagno-
sis and non-adherence to adjuvant therapy were the main 
predictors of local recurrence (P < 0.001).
Discussion
Malignant tumors of the head and neck constitute one 
of the most frequent malignancies worldwide with about 
Table 1 Distribution of  patients according to  anatomical 
tumor site
Anatomical tumor site Frequency Percentages
Oral cavity 129 37.3
Pharynx 56 16.2
Larynx 48 13.9
Nasal/paranasal sinuses 39 11.3
Neck region 37 10.7
Salivary glands 26 7.5
Scalp 7 2.0
Ears 4 1.2
Table 2 Distribution of  histopathological type according 
to HIV status
* Indicates that it is statistically significant
Histopathological 
type




Carcinomas 4 (1.9) 202 (98.1) 0.674
Lymphomas 11 (12.5) 77 (87.5) 0.011*
Sarcomas 10 (26.3) 28 (73.7) 0.001*
Neuroendocrine 
tumors
0 (0) 14 (100) –
Table 3 Distribution of  patients according to  the type 
of surgical procedure performed (N = 196)
Surgical procedure performed Frequency Percentages
Tumor excision 120 61.2
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half a million new cases diagnosed per year [5], and 
their incidence appears to be increasing in developing 
countries [4]. In this study, cancers of the head and neck 
accounted for 9.5 % of all malignancies which is compa-
rable with the global incidence of 5–50 % [6]. Our figure 
is comparable with a figure of 10 % that was reported in 
Yemen [20], but higher than that reported in the USA 
(5 %) [7–9] and Kuwait (7.4 %) [20]. A high figure of 40 % 
was observed in some Asian countries [21]. This differ-
ence in the incidence of head and neck cancers in these 
studies may be explained in part by the differences in 
exposure to risk factors such as cigarette smoking and 
alcohol consumption, viruses, diet and familial risks [20, 
21]. The incidences of these diseases are higher in regions 
of the world where tobacco use and alcohol consumption 
is high [20].
In this study, the majority of patients were in the 
fourth decades of life. This is in keeping with most pre-
vious reports from other African studies [12, 15, 16, 19]. 
Overall, head and neck cancers seem to affect Africans 
at a younger age than in Caucasians [2, 5, 12, 15, 16, 19, 
20]. The reasons for higher percentage of occurrence in 
younger age group among African are not so clear but 
they may be connected to issues of race, genetics, poverty 
and behavioral practices. Shorter life expectancy in Afri-
cans compared with Caucasians, and earlier exposure to 
risk factors have also been speculated [2, 20].
The male to female ratio of 2.1:1 in this study, is in 
agreement with 1:1 to 2.3:1 reported by Lilly-Tariah et al. 
[12] in which a meta-analysis review of twenty-seven 
relevant published articles on head and neck cancers in 
Nigeria from 1968 to 2008 was undertaken, but differs 
from the slight female preponderance (1:1.02) observed 
by Ologe et  al. [16] in Nigeria. The reason for the male 
predominance in these studies could be attributed to 
the fact that some of the habits that have been associ-
ated with the occurrence of head and neck cancer, such 
as smoking and use of alcoholic beverages, are strongly 
associated with male gender [22]. The male preponder-
ance in this study may be explained by the high rate of 
cigarette smoking and alcohol consumption by men as 
compared to females in the Tanzanian society as shown 
in this study.
Head and neck cancer has been reported in most 
studies to be more prevalent in people with low socio-
economic status [12, 15, 16, 19, 20]. This finding is 
reflected in our study in which the majority of patients 
were farmers coming from rural areas located a consid-
erable distance from the study area and most of them 
had either primary or no formal education and were 
unemployed. This observation has an implication on the 
accessibility of healthcare facilities and awareness of the 
disease.
In the present study, the majority of patients presented 
late with advanced stage of cancer which is in keeping 
with other studies in developing countries [15, 16, 19, 
20]. Late presentation in these countries may be due to 
ignorance, poverty, poor access to health services, and 
patients consulting traditional healers and using tradi-
tional medicines. Late presentation of cases is an area 
of head and neck cancer care in our center that requires 
urgent attention. We could not establish the reasons for 
late presentation in this study, owing to its retrospective 
nature. Detecting primary cancer at an early stage con-
tributes to improved chances for successful treatment 
and thus for survival.
The role of alcohol and tobacco in carcinogenesis of 
head and neck cancers is well documented [6, 12, 22, 23]. 
In our study, history of alcohol consumption and smoking 
was documented in 69.9 and 76.6 % of patients, respec-
tively. Using alcohol and tobacco together increases the 
risk of developing head and neck cancers even more [7]. 
The joint effect of alcohol and smoking when consumed 
together are potentiated and the final relative risk is mul-
tiplied [6, 7]. More recent data from case–control studies 
and meta-analyses indicate that HPV-16 is an independ-
ent risk factor for oral and oropharyngeal carcinomas 
[21]. Human papilloma virus (HPV) status was not 
known as the facility for testing HPV was not available at 
our centre.
In this study, the oral cavity was the most frequent ana-
tomical site for the head and neck cancers which is in 
agreement with other studies [5, 20], but at variance with 
a report on the overall pattern of head and neck can-
cers from Nigeria, in which nasopharynx, nose and lar-
ynx were the three most common sites [2, 16]. The nose 
and paranasal sinuses accounted for the highest number 
of cases followed by the nasopharynx and least being 
the scalp in a study done by Onotai and Nwogbo [24] in 
Nigeria. Onyango and Macharia [19] in Kenya reported 
the larynx as the most common site affected followed 
by the tongue. The reason for this anatomical difference 
among these countries is not clear but may have to do 
with geographical location and the socio-cultural prac-
tice of the people in that region [24].
As reported in a study by Donkor and Boateng [25] 
in Ghana, most of patients in this study presented with 
advanced stage (III–IV). The large number of patients 
with advanced stage at the time of diagnosis may be 
attributed to by the fact that the majority of patients in 
this study presented late to our health facility. The major-
ity of patients in our environment, especially those in the 
rural areas lack the financial means to access modern 
health facilities due to high poverty level and this is fur-
ther compounded by harmful traditional beliefs and prac-
tices which make them visit the herbalist for solutions to 
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their health problems so that by the time they present to 
us, their tumors would have reached advanced stages and 
hence a poor outcome in management.
In this study, lymph node and distant metastases at 
the time of diagnosis were recorded in 29.5 and 28.3  % 
of cases, respectively. A similar metastatic pattern was 
reported by other authors [15, 16, 19]. High lymph node 
and distant metastases in this study is attributed to the 
late presentation in the majority of patients.
In agreement with the literature worldwide [26–28], the 
majority of head and neck cancer in this study was epi-
thelial in origin (carcinomas) and was mostly squamous 
cell carcinoma. By contrast, Amusa et al. [29] in Nigeria 
found that lymphoma was the most frequently diagnosed 
head and neck cancer. The prevalence of cancers, espe-
cially carcinomas among farmers could be related to the 
long exposure to the sun and composition of some of the 
chemical fertilizers which may contain substances with 
carcinogenic risks [29].
Pretreatment workup of the head and neck cancers 
is important to decide on indication and extent of the 
treatment [30]. Histopathological investigation of the 
collected specimen is an essential part of work up as it 
provides a histological diagnosis enabling the commence-
ment of early and proper treatment. Fine needle aspi-
ration biopsy is preferable to open biopsy of a cervical 
lymph node for the reasons that there is no tumor spread, 
no inconvenient scar to distort future surgical interven-
tion, no delay between diagnosis and treatment and its 
simplicity. When a diagnosis of malignancy cannot be 
made by needle biopsy, then an open biopsy can be done 
provided it can be followed by a frozen section and a con-
comitant definitive neck dissection if peroperative posi-
tive histological diagnosis is obtained [31]. Open cervical 
lymph node biopsy can alter patterns of lymphatic drain-
age for up to 1 year following surgery [32] and creates a 
scar which distorts future surgical intervention therefore 
altering the outcome of treatment [31, 32]. Facilities for 
frozen section are not available in our center and delay 
in getting histopathology results from the open cervical 
biopsies and also following panendoscopy as seen in our 
study further compounds our patients’ problems as their 
tumors and disease process progresses further with even-
tual poor outcome. Accurate staging at the time of the 
diagnosis of head and neck cancer is critical for selection 
of the appropriate treatment strategy. Therefore, optimiz-
ing pre-treatment imaging in the diagnostic work-up is 
of great importance. CT and MRI are the corner stones 
of diagnostic work-up. Technical improvements will 
increase the value of these techniques even further. PET 
and PET-CT became a standard imaging techniques for 
head and neck patients. It may be helpful for the detec-
tion of occult primary tumours, but its sensitivity for the 
detection of occult lymph node metastases is too low. 
Alternatively, the sentinel node procedure may be suffi-
ciently accurate to avoid elective treatment of the neck. 
Screening for distant metastases should be performed 
only in head and neck cancer patients with high risk fac-
tors by FDG-PET-CT [33]. However, CT scan and MRI 
were not available in this study, which challenged our 
management, as this limited the tumour staging.
In this study, HIV seroprevalence was found to be 
7.2  %, a figure that is significantly higher than 5.3  % in 
the general population in Tanzania [34]. We could not 
establish the reason for the high HIV seroprevalence in 
our study. Failure to detect HIV infection during window 
period and exclusion of some patients from the study 
might have underestimated the prevalence of HIV infec-
tion among these patients. Patients with HIV infection 
have been reported to have a significantly higher risk of 
developing head and neck cancers [26]. The proportion 
of HIV infected patients in the current study was sig-
nificantly higher in patients with lymphomas (12.5  %) 
and sarcomas (26.2 %) than in patients with carcinomas 
(1.9 %). The risks of several different cancer types are ele-
vated in HIV-infected individuals due to behavioral and 
biological characteristics, immunodeficiency, and poten-
tially chronic inflammation and immune dysfunction/
senescence [26].
In the present study, the staging of head and neck can-
cers before definitive treatment was done according to 
the TNM (tumour, node, and metastasis) system thor-
ough clinical evaluation and work up. However, one of 
the salient and challenging outcomes of this analysis is 
the poor levels of staging for cancer. Most of the cancers 
were poorly staged or the records could not be verified. 
However, since the records indicated only the clinical 
staging or TNM system, it was possible that most of the 
unknown were merely late presentations either at stages 
III and IV. However, the unusually large percentage of 
head and neck cancers with no clinical stage indicated in 
the healthcare records calls for urgent remedial action by 
all concerned parties.
Surgery, radiotherapy and chemotherapy either alone 
or in combination are the standard modalities of treat-
ment of head and neck cancers [30, 35, 36]. The his-
tologic cell type and the stage of the disease determine 
the choice of treatment. Lymphomas respond satisfac-
torily to chemotherapy. Early stages of head and neck 
carcinomas can be treated satisfactorily (cured) with 
radiotherapy alone or surgery alone. Stages III and IV 
carcinomas require a combination of salvage surgery 
and radiotherapy [36]. Radiotherapy may be used before 
or after surgery [23, 30]. Chemotherapy is also useful 
in cases of metastasis and recurrence. Chemotherapy 
may also be used for induction chemotherapy before 
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radiotherapy [36]. Frozen section is a standard procedure 
to ascertain safety or otherwise of tumour margins in 
most centres around the world. In Tanzania, frozen sec-
tions are not routinely done in the management of head 
and neck cancer. In this study, surgery given either alone 
or in combination with radiotherapy and chemotherapy 
were performed in more than half of patients. The rea-
son for the low rate of head and neck cancer resection in 
our series may be explained by the fact that the majority 
of patients presented late with inoperable tumors at the 
time of diagnosis, for which only palliative treatment was 
possible. Only 4.1 % of the patients in our series had head 
and neck cancer resection with curative intent which is in 
agreement with other studies in developing countries [12, 
35, 36]. Radiation therapy has been shown to improve 
local control rates in locally advanced head and neck 
cancers [36]. However, in our study only 9.5 % of patients 
who required radiotherapy had access to this form of 
treatment. This concurs with other studies in resource-
limited countries [35, 36]. Failure to access this modal-
ity of treatment in our patients can be explained by the 
fact that radiotherapy is not available in our center and 
therefore patients requiring this form of treatment had to 
travel long distances to receive radiotherapy at the only 
oncological center in the country. This sad observation 
calls for urgent establishment of radiotherapy services in 
our center. In the present study, only 16.8 % of patients 
received chemotherapy despite the establishment of an 
oncological unit in our center in 2009. In resource poor 
countries such as Tanzania, non-adherence to chemo-
therapy is a major challenge in cancer treatment includ-
ing head and neck cancers. Reasons for non-adherence 
in most developing countries include financial difficulty, 
resorting to alternative treatment and drug side effects 
[12, 36]. We could not establish the reasons for non-
adherence to chemotherapy in our study owning to the 
retrospective nature of the study. Further prospective 
study is needed to explain this observation. In developed 
countries, chemoradiation is widely used as an organ-
sparing treatment strategy in patients with head and neck 
cancers. Compared to radiotherapy alone it has an 8  % 
advantage in terms of locoregional control and survival 
rates [35]. In this study, only 2 (0.6 %) patients who had 
squamous cell carcinoma of the oral cavity and nasophar-
ynx received chemoradiation therapy at the Tanzanian 
Oncological centre located a considerable distance from 
the study area.
The overall mortality rate in this study was 24.3 %, a fig-
ure which is higher than 14 % reported by Kumar et al. 
[37], but low compared with 32.6 % that was reported by 
Adeyi and Olugbenga [35] in Nigeria. The commonest 
causes of deaths were advanced malignancy, complica-
tions of HIV/AIDS and sepsis. The high mortality rate in 
this study is attributed to advanced age at diagnosis, late 
presentation, HIV seropositivity, CD4+ count below 200 
cells/μl, stage of the cancer and presence of metastasis at 
the time of diagnosis. Addressing these factors responsi-
ble for high mortality in our patients is mandatory to be 
able to reduce mortality associated with this disease.
In keeping with other authors in developing coun-
tries [12, 35, 38], the follow-up of patients in this study 
was generally poor as more than 60 percent of patients 
were lost to follow-up at the end of 5 years. We could 
not establish the reasons for the large number of loss to 
follow up in this study. This calls for further studies to 
explain this state of affairs.
Despite recent advances in the diagnosis and treatment 
of head and neck cancer, there has been little evidence 
of improvement in 5-year survival rates over the last few 
decades [35, 38]. In this study, the overall 5-year survival 
rate of 20.6  % is significantly low compared to the sur-
vival rate for patients with advanced (stage III–IV) head 
and neck cancers managed in developed countries which 
ranges from 30 to 50 percent [19, 35, 38]. The lower sur-
vival rate in this study is consistent with data from most 
cancer sites in developing countries and is likely to be due 
to late diagnosis, late referrals, poor access of patients to 
our centre and the reliability on traditional healers and 
medicine man [35]. In our patients, the factors that sig-
nificantly affect prognosis were age of patient at diagno-
sis, stage of disease, extent of lymph node involvement, 
HIV seropositivity and CD4+ count below 200 cells/μl.
Despite advances in the treatment of head and neck 
cancer, 15–50 percent of patients will develop recurrent 
disease [39]. In this study, local recurrence of cancer was 
reported in 23.4 % of cases, a figure which is higher than 
that reported in other studies [12, 19, 35]. The reasons for 
the high rate of local recurrence in the present study may 
be attributed to advanced stage of cancer at the time of 
diagnosis, presence of metastasis at the time of diagnosis, 
positive resection margins and non-adherence to adju-
vant therapy.
This study has demonstrated that the management of 
head and neck cancers poses diagnostic and therapeutic 
challenges at Bugando Medical Centre and contributes 
significantly to high morbidity and mortality among these 
patients. Factors such as late presentation, inaccessible 
health facilities and limited diagnostic and therapeutic 
tools have contributed to the eventual poor outcome in 
the management of patients with head and neck malig-
nancies in our environment. Delay in the availability of 
histopathology results following biopsies and the practice 
of subjecting patients with head and neck lymphadenop-
athy to open lymph node biopsy with attendant compli-
cations such as scar formation and tumor spread are the 
hallmarks of the disease in this part of the world [35].
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The major limitation of this study is the fact that infor-
mation about some patients was incomplete in view of 
the retrospective nature of the study and poor docu-
mentation might have introduced some bias in our find-
ings. Also, this study included only patients who were 
evaluated and treated at a single institution, which may 
not reflect the whole population in this region, despite 
the fact that approximately seventy percent of oncologic 
patients in northwestern Tanzania are managed at our 
center. Lack of advanced staging investigations such as 
CT scan and MRI challenged our management, as this 
limited the tumour staging. In addition, follow-up was 
poor and irregular and so it was difficult to know the 
exact time of recurrence or death. Large number of loss 
to follow up was also a potential limitation of this study 
as this may have underestimated the local recurrence and 
overall survival rate. However, despite these limitations, 
the study has provided local data that can help health-
care providers in the management of patients with head 
and neck cancer. The challenges identified in the man-
agement of head and neck cancer in our setting need to 
be addressed in order to deliver optimal care for these 
patients.
Conclusion
Head and neck cancers are not uncommon at Bugando 
Medical Centre and show a trend towards a relative 
young age at diagnosis and the majority of patients pre-
sent late with advanced stage cancer. Lack of awareness 
of the disease, poor accessibility to healthcare facilities, 
limited diagnostic and therapeutic facilities, the delay in 
the availability of histopathology results following biop-
sies, poor accessibility to adjuvant therapy, the high cost 
of care, a high morbidity and mortality, poor follow up 
and loss to follow up are among the hallmarks of the 
disease in this region and pose a great challenge in the 
management of these patients. Therefore, public enlight-
enment, early diagnosis, and effective cost-effective treat-
ment and follow-up are urgently needed to improve 
outcomes of these patients in our environment. There is 
a need for the government to provide treatment funds for 
these poor patients as a significant number of patients 
were unable to complete treatment due to lack of funds. 
Establishment of radiotherapy services at our centre is 
highly recommended.
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